US drugmaker Pfizer has agreed to pay $2.3bn (£1.4bn) in the largest healthcare fraud settlement in the history of the Department of Justice.

美国制药商Pfizer决定支付23亿美元赔款，这是美国司法部历史上最大的医疗保健欺诈案。

Pfizer has said it wants to put the "trust issues" behind it

It follows the firm being found to have illegally promoted four drugs as treatments for conditions different to those which regulators had approved.

A subsidiary of the firm pleaded guilty to misbranding drugs "with the intent to defraud¹（欺骗） or mislead".

US officials said Pfizer would have to enter a corporate² integrity（诚实，正直） agreement.

It will be subject to additional public scrutiny³（监督） by requiring it to make "detailed⁴ disclosures" on its website.

Pfizer's general counsel said: "We regret certain actions taken in the past, but are proud of the action we've taken to strengthen our internal controls."

Acting⁵ US attorney for the District of Massachusetts, Mike Loucks said that "the size and seriousness of this resolution, including the huge criminal fine, reflect the seriousness and scope of Pfizer's crimes".

The company faces a criminal fine of $1.195bn and a subsidiary company of Pfizer - Pharmacia & Upjohn - will forfeit⁶ $105m.

The remaining $1bn fine was levied⁷（征收，课税） to resolve the allegations under the civil False Claims Act.

Four drugs

The civil settlement also relates to allegations that Pfizer paid bribes⁸ and offered lavish⁹（大方的，浪费的） hospitality to healthcare providers to encourage them them to prescribe four of the company's drugs. These were Bextra, an anti-inflammatory drug, Geodon, an anti-psychotic drug, Zyvox, an antibiotic¹⁰ and Lyrica, an epilepsy（癫痫症） treatment.

The investigation¹¹ was trigged by allegations made by six whistleblowers（告发者）. They will receive $102m of the civil fines paid by Pfizer.

"Although these types of investigations¹² are often long and complicated and require many resources to achieve positive results, the FBI will not be deterred¹³ from continuing to ensure that pharmaceutical¹⁴ companies conduct business in a lawful¹⁵ manner," said Kevin Perkins, FBI assistant director, Criminal Investigative Division.

The pharmaceutical firm said earlier this year that it would pay the fine "to put issues that diminish trust behind us".

Pfizer reported a 90% drop in profit to $268m in the fourth quarter of 2008, because of the $2.3bn legal settlement, indicating that the company was aware they would be paying this sum before the terms of the deal with the Department of Justice were announced.